In recent trading session, Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) saw 1.31 million shares changing hands at last check today with its beta currently measuring 0.65. Company’s recent per share price level of $14.42 trading at $0.13 or 0.91% at last check today assigns it a market valuation of $16.52B. That most recent trading price of TEVA’s stock is at a discount of -58.11% from its 52-week high price of $22.80 and is indicating a premium of 13.52% from its 52-week low price of $12.47. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 12.98 million shares which gives us an average trading volume of 13.13 million if we extend that period to 3-months.

For Teva- Pharmaceutical Industries Ltd. ADR (TEVA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.73. Splitting up the data highlights that, out of 8 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0.46 in the current quarter.

Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) trade information

Upright in the green today for gaining 0.91%, in the last five days TEVA remained trading in the green while hitting it’s week-highest on Wednesday, 04/23/25 when the stock touched $14.42 price level, adding 1.23% to its value on the day. Teva- Pharmaceutical Industries Ltd. ADR’s shares saw a change of -34.57% in year-to-date performance and have moved 7.37% in past 5-day. Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) showed a performance of -8.15% in past 30-days. Number of shares sold short was 32.39 million shares which calculate 2.77 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 28 to the stock, which implies a rise of 48.5% to its recent value today. Analysts have been projecting 28 as a low price target for the stock while placing it at a high target of 28. It follows that stock’s current price would drop -94.17% in reaching the projected high whereas dropping to the targeted low would mean a loss of -94.17% for stock’s current value.

Teva- Pharmaceutical Industries Ltd. ADR (TEVA) estimates and forecasts

This year revenue growth is estimated to rise 4.22% from the last financial year’s standing.

5 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 3.99B for the same. And 4 analysts are in estimates of company making revenue of 4.36B in the next quarter. Company posted 3.82B and 4.16B of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -9.62% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 3.02% while estimates for its earnings growth in next 5 years are of 6.26%.

Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA)’s Major holders

Insiders are in possession of 0.00% of company’s total shares while institution are holding 60.48 percent of that, with stock having share float percentage of 60.48%. Investors also watch the number of corporate investors in a company very closely, which is 60.48% institutions for Teva- Pharmaceutical Industries Ltd. ADR that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at TEVA for having 42.99 million shares of worth $698.55 million. And as of 2024-06-30, it was holding 3.7942 of the company’s outstanding shares.

The second largest institutional holder is FMR LLC, which was holding about 41.98 million shares on 2024-06-30. The number of shares represents firm’s hold over 3.7051 of outstanding shares, having a total worth of $682.15 million.

On the other hand, Fidelity Contrafund and iShares Trust-iShares Core MSCI EAFE ETF are the top two Mutual Funds which own company’s shares. As of Feb 28, 2025 , the former fund manager was holding 18.74 shares of worth $270.82 million or 1.64% of the total outstanding shares. The later fund manager was in possession of 7.16 shares on Mar 31, 2025 , making its stake of worth around $103.51 million in the company or a holder of 0.62% of company’s stock.